The thrombotic issue is emerging in this pandemic causing a blood clotting problem which is considered as a complication. Blood clotting is a universal phenomenon and it is a protective mechanism in external cellular and tissue injury. But, due to pandemics, thrombosis or blood clot is considered a complication that needs special attention. There are some presentations of blood clotting showing up in COVID-19 patients as a complication. The autopsy report of the COVID19 patients has revealed clots in the small vessels of the lung, liver, heart, kidney which are responsible for stroke and heart problems. 

D- dimer test for COVID 

We have seen people suffering from COVID having thrombotic issues. Many doctors are coming forward and prescribing D-dimer tests to COVID patients to exclude the complication of thrombosis from this pandemic. Critical COVID patients are reported to have high levels of blood clotting or elevated levels of D- dimer. 

Research regarding the blood clots this pandemic 

Scientists are keen on finding out why blood clots form as a post COVID complication. According to a study from the Royal College of Surgeons in Ireland University of Medicines and health science, research is going on to know the main reason behind this blood clot complication. 

The study has shown some evidence that the von Willebrand Factor (vWF) is severely disrupted in critically ill COVID 19 patients. vWF factor is a protein that causes and promotes blood clots along with an enzyme ADAMTS13 which regulates clotting. The researchers took and examined the samples from COVID-19 patients and compared it with the NON-COVID patients. The blood of COVID patients had higher levels of pro- clotting factors which is von Willebrand Factor (vWF) and lower levels of anti-clotting enzymes. As per the research-based study, blood clotting is a major cause of death in COVID19 patients. 

Blood clots are a serious problem seen in children 

Blood clots may be a critical problem in children making them difficult to deal with. Apart from COVID19, any cases of cancer, congenital heart disease, hemophilia, or venous thromboembolism may lead to many complications. This may require admitting the child to the Intensive Care Unit (ICU). The complications of a blood clot in children are as follows: 

FDA approves Pradaxa 

Pradaxa is the first approved blood-thinning medication that children can take by mouth. Apart from this, there was an injectable that was approved earlier for children for blood clot treatment. The FDA is committed to taking care of the patients, especially children of this COVID pandemic. With the approval of Pradaxa, a blood-clotting medicine, pediatric patients have a good therapeutic option to treat and prevent potentially deadly blood clots. The safety and efficacy of treating blood clots in the pediatric population is evaluated in 267 children under the age of 18 years who were diagnosed with blood clotting issues. The FDA has granted approval of Pradaxa to Boehringer Ingelheim Pharmaceuticals Inc.